{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "EVH",
  "name": "Evolent Health, Inc",
  "url": "https://orbyd.app/dossiers/EVH/",
  "json_url": "https://orbyd.app/dossiers/EVH.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "The late-June retail bounce has fully unwound — EVH traded ~$5.76 on 2026-07-07, back under the $6.59–6.86 consensus target band and well under Truist's flat $7. Nothing carries the name now except the confirmed 2026-08-06 Q2 print, which is a binary on whether oncology medical-cost trend has stabilized.",
  "invalidation_trigger": "A weekly close below $5.00 loses the June bounce base and confirms the retail leg is fully retraced; secondary break is the 2026-08-06 Q2 print landing without a credible medical-cost-trend stabilization datapoint, which removes the last dated reason to own it.",
  "catalyst_date": "2026-08-06",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-27",
  "invalidation_fired": true,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q2 2026 earnings CONFIRMED: Thursday 2026-08-06, before market open, call 8:00 a.m. ET. Prior dossier carried this as ~early August unconfirmed — now dated.",
    "The late-June retail spike (RSI 73, +75% social velocity into 2026-06-29) has round-tripped: ~$5.76 on 2026-07-07. The squeeze character is spent; the name now trades as a pre-print binary rather than a flow story.",
    "Truist's 2026-06-30 Buy. A re-upgrade or a target lift above $7 would be the first genuine re-acceleration signal.",
    "Consensus target band is tight and low: ~$6.59–6.86 average across 14–20 covering analysts, high $10, low $5. The Street models modest upside, not a re-rate.",
    "Privia Health acquired Evolent's ACO business for $100M cash plus up to $13M earnout (announced 2025-09-29, ~120,000 attributed lives, closed Q4 2025). Proceeds went to paying down high-cost debt, cutting leverage ~0.3x. This is a completed 2025 divestiture, NOT a fresh catalyst — do not re-date it.",
    "FY2026 consensus: revenue ~$2.49B roughly flat, loss narrowing from about -$0.818 to -$0.725 per share. A shrinking-loss, flat-revenue model is not an accelerating narrative.",
    "Core unresolved risk: performance-based specialty contracts stay exposed to oncology cost inflation and forward medical-cost-trend visibility remains poor.",
    "Prices sourced from public quotes as of 2026-07-07; re-confirm against a live quote before acting on any level in this note."
  ],
  "body_markdown": "## Current Thesis\n\nThe bounce is over. Evolent spiked on retail flow into 2026-06-29 — RSI 73, social velocity roughly +75% — The round trip took about a week. What remains is a specialty-care manager carrying performance risk on oncology, cardiology and musculoskeletal cost trends, running ~$2.49B of roughly flat FY2026 revenue against a consensus loss narrowing from about -$0.818 to -$0.725 per share, with one dated event on the board: Q2 results before the open on Thursday 2026-08-06, call at 8:00 a.m. ET.\n\nThat print is the whole story now. Everything else — the sector bid, the retail spike, the divestiture — has already been priced or already unwound. A cost-trend-exposed operator heading into a print with poor forward visibility is a coin-flip dressed as a setup, and the coin is being flipped in eighteen days.\n\n## Bull Case\n\n- Balance sheet is materially cleaner than a year ago: the ACO business sold to Privia Health for $100M cash plus up to $13M in performance payments (announced 2025-09-29, ~120,000 attributed lives, closed Q4 2025), with proceeds applied to high-cost debt and leverage down roughly 0.3x.\n- The Street has not abandoned it. Across 14–20 covering analysts the rating distribution skews heavily to Buy, with an average target near $6.59–6.86 versus ~$5.76 on 2026-07-07 — roughly 15–19% implied upside, high target $10.\n- Operating leverage off a depressed base is real: if oncology cost trend normalizes, the same performance contracts that cratered earnings in 2024–2025 swing the other way, and the FY2026 loss trajectory (-$0.818 → -$0.725) is already bending.\n- Strategic optionality persists at a single-digit share price. The Privia transaction demonstrated that Evolent's asset pieces have identifiable buyers at identifiable prices.\n\n## Bear Case\n\n- Truist went Buy. A downgrade that leaves the target untouched is a desk saying the move is finished, not that the business broke.\n- The retail leg fully retraced. From the 2026-06-29 spike to ~$5.76 on 2026-07-07 there was no higher low, no base, no volume shelf — the flow left as fast as it arrived, which is what unsupported bounces do.\n- Flat revenue is the tell on narrative: ~$2.49B forecast for FY2026 with no growth line means the equity story is entirely margin-repair, and margin repair depends on a medical-cost variable management has repeatedly failed to forecast.\n- Selling the ACO unit to service debt shrinks the revenue base. Deleveraging via divestiture is defensive capital allocation, and it removes a diversifying, growing line from the mix.\n- Consensus targets cluster in a narrow $5–$10 band around a $6.86 midpoint. Nobody covering this name models a re-rate; they model a recovery to modestly-less-broken.\n\n## Setup & Price Structure\n\nPrice at ~$5.76 (2026-07-07) sits between the $5.00 area that defines the June bounce base and the $7 overhead the sell-side has now marked twice — once as an upgrade target on 2026-06-12, once as a downgrade cap on 2026-06-30. That is a $2 box with a confirmed binary landing inside it on 2026-08-06.\n\nThe structural problem is that the June advance produced no accepted price above $6. A move that spikes on social velocity and gives the entire gain back within a week has built no shelf to retest, so there is no defined-risk long available — a buyer here is guessing at support rather than leaning on it. The constructive sequence would be a base above $5.00 that holds a higher low through the print, followed by a reclaim of $6.50–7.00 on an actual cost-trend datapoint. Absent that, the honest read is stand aside; there is no entry, only a bet on an earnings number.\n\nFor anyone underwriting the recovery thesis, the position to want is one established after 2026-08-06 with the medical-cost-trend disclosure in hand, sized small. Entering before the print converts a fundamental thesis into a binary wager on a metric with a poor forecasting record.\n\n## Catalyst Calendar (next 30 days)\n\n- No FDA, regulatory, contract-award or investor-day date is scheduled inside the window. Nothing else is dated.\n\n## Elapsed catalysts\n\n- **2026-08-06 (confirmed)** — Q2 2026 results, before market open; conference call 8:00 a.m. ET. The dominant event. Watch: medical-cost trend commentary on the oncology book, FY2026 revenue guide against the ~$2.49B consensus, EPS path against the -$0.725 full-year estimate, and post-divestiture net leverage. *(passed 3d ago)*\n- **Ongoing through 2026-08-06** — analyst revisions. Truist's flat $7 on 2026-06-30 is the marker; any target lift above $7, or a reversal of that Hold, is the first evidence the deceleration call is being retracted. *(passed 3d ago)*\n\n## What Would Change Our Mind\n\n- A weekly close back above $7.00 on a fundamental datapoint — a large contract award, a cost-trend disclosure showing sequential improvement, or a target raise above the $7 ceiling — would mark the sell-side cap being taken out and would restart the recovery narrative.\n- Q2 on 2026-08-06 printing revenue above the ~$2.49B run-rate with an explicit statement that oncology cost trend has stabilized, plus a raised FY2026 EPS guide against the -$0.725 consensus, would convert this from a broken model into a genuine earnings inflection worth sizing.\n- Insider buying or a 13D-style accumulation at these levels would signal that people with the medical-cost data consider $5.76 mispriced.\n- Conversely, a weekly close below $5.00 confirms the June bounce was noise and re-opens the multi-year downtrend; guidance cut or a fresh contract-loss disclosure on 2026-08-06 would do the same on fundamentals.\n\n## Correlation Notes\n\n- Trades with the value-based-care cohort — Agilon Health and Oscar Health moved together on the 2026-06-04 sector bid, and Evolent participated late rather than leading, which is how the lower-quality name in a group behaves.\n- Privia Health is now both a peer and a counterparty following the ACO purchase; Privia's commentary on MSSP economics reads as a forward indicator for the assets Evolent retained.\n- The dominant macro sensitivity is the managed-care medical-loss-ratio cycle. Large-payer utilization commentary in the same earnings season leads specialty-care managers, so payer prints ahead of 2026-08-06 carry read-through.\n- Retail-flow correlation is high and unstable: the name moved on social velocity into 2026-06-29 without any peer or fundamental confirmation, so beta to broad small-cap speculative flow currently exceeds beta to healthcare fundamentals.\n- Rate sensitivity is above-average for a healthcare services name given the leverage profile, even after the ~0.3x reduction from the divestiture proceeds.",
  "first_seen": "2026-06-29",
  "last_analyzed": "2026-07-19T12:13:11+00:00",
  "last_synthesized": "2026-07-19",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}